We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$7.53B
AUM Growth
+$567M
Cap. Flow
+$2.93M
Cap. Flow %
0.04%
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$20.9M
2
INCY icon
Incyte
INCY
+$16.3M
3
ISRG icon
Intuitive Surgical
ISRG
+$14.4M
4
DXCM icon
DexCom
DXCM
+$14.1M
5
CNC icon
Centene
CNC
+$13.5M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$40.9M
2
UNH icon
UnitedHealth
UNH
+$38.4M
3
ELV icon
Elevance Health
ELV
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Industrials 0.38%
3 Miscellaneous 0.03%
4 Energy 0.03%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMCL icon
76
Omnicell
OMCL
$1.57B
$26.1M 0.35%
518,384
+104,100
+25% +$6.25M
MRSN
77
DELISTED
Mersana Therapeutics
MRSN
$25.1M 0.33%
171,304
+8,000
+5% +$1.35M
ADPT icon
78
Adaptive Biotechnologies
ADPT
$3.87B
$22.6M 0.3%
2,960,131
-319,489
-10% -$2.49M
CSTL icon
79
Castle Biosciences
CSTL
$1.01B
$22.2M 0.3%
944,312
+2,441
+0.3% +$56.6K
PHR icon
80
Phreesia
PHR
$679M
$21.6M 0.29%
666,419
– –
KZR
81
DELISTED
Kezar Life Sciences
KZR
$21.3M 0.28%
303,100
– –
PRVA icon
82
Privia Health
PRVA
$2.64B
$20.5M 0.27%
900,666
+385,636
+75% +$10.7M
RMD icon
83
ResMed
RMD
$32.9B
$20.5M 0.27%
98,275
+13,663
+16% +$3M
EPIX
84
DELISTED
ESSA Pharma
EPIX
$19.9M 0.26%
7,898,583
+2,000,000
+34% +$5.74M
SRRK icon
85
Scholar Rock
SRRK
$6.74B
$19.5M 0.26%
2,152,025
– –
ILMN icon
86
Illumina
ILMN
$33B
$19.2M 0.25%
97,564
+9,231
+10% +$1.91M
CVS icon
87
CVS Health
CVS
$124B
$19M 0.25%
204,205
-20,909
-9% -$2.02M
HOLX
88
DELISTED
Hologic
HOLX
$18.2M 0.24%
243,171
-8,241
-3% -$587K
LEGN icon
89
Legend Biotech
LEGN
$4.19B
$17.7M 0.24%
354,789
-270,672
-43% -$13.1M
ALGN icon
90
Align Technology
ALGN
$11.3B
$16.7M 0.22%
79,194
+4,255
+6% +$852K
BAX icon
91
Baxter International
BAX
$13.4B
$16.3M 0.22%
320,681
+1,133
+0.4% +$60.9K
DOCS icon
92
Doximity
DOCS
$4.7B
$15.1M 0.2%
448,579
+255,140
+132% +$7.79M
GBIO
93
DELISTED
Generation Bio
GBIO
$14.3M 0.19%
362,728
– –
TXG icon
94
10x Genomics
TXG
$8.16B
$11.8M 0.16%
324,746
+70,612
+28% +$2.31M
REGN icon
95
Regeneron Pharmaceuticals
REGN
$85.2B
$11.3M 0.15%
15,678
-1,711
-10% -$1.26M
GILD icon
96
Gilead Sciences
GILD
$187B
$11.2M 0.15%
130,343
+32,489
+33% +$2.57M
NVRO
97
DELISTED
NEVRO CORP.
NVRO
$10.3M 0.14%
260,835
– –
AMGN icon
98
Amgen
AMGN
$236B
$10.2M 0.14%
38,939
-6,257
-14% -$1.68M
AVTR icon
99
Avantor
AVTR
$10.1B
$9.95M 0.13%
471,621
-31,386
-6% -$650K
BDTX icon
100
Black Diamond Therapeutics
BDTX
$122M
$9.72M 0.13%
5,400,839
+683,726
+14% +$1.23M
2 3
4
5 6

Similar funds

SP
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
LPPI
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
NHC
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Bellevue Group's Q4 2022 Portfolio in Review

As of Q4 2022, Bellevue Group held 184 positions worth $7.53B, up 8.1% from $6.97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group's Q4 2022 filing shows 8 new, 71 increased, 51 reduced and 13 closed positions. Its largest new stake was Natera: 173,812 shares worth $6.98M. The largest sale was Abiomed Inc, an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Miscellaneous.

  • Bellevue Group's largest Q4 2022 buy was Natera: 173,812 shares worth $6.98M.
  • Bellevue Group added most to Fate Therapeutics in Q4 2022, an estimated $20.9M increase.
  • Bellevue Group's biggest Q4 2022 reduction was UnitedHealth, cutting an estimated $38.4M.
  • Bellevue Group fully exited Abiomed Inc in Q4 2022, selling an estimated $40.9M.
  • Bellevue Group's ten largest holdings make up 36% of its $7.53B portfolio in Q4 2022.
  • Bellevue Group opened 8 new positions and closed 13 in Q4 2022.
  • Bellevue Group's portfolio value rose 8.1% quarter-over-quarter to $7.53B.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.